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The intent of this review is to discuss and comment on common clinical scenarios in which 
contrast-enhanced ultrasonography (CEUS) may play a decisive role and to illustrate important 
points with typical cases. With the advent of CEUS, the scope of indications for ultrasonography 
has been dramatically extended, and now includes functional imaging and tissue characteriza-
tion, which in many cases enable tumor diagnosis without a biopsy. It is virtually impossible to 
imagine the practice of modern medicine as we know it in high-income countries without the 
use of imaging, and yet, an estimated two thirds of the global population may receive no such 
care. Ultrasound imaging with CEUS has the potential to correct this inequity.
Keywords: Abdomen; Image enhancement; Ultrasonography; Contrast media; Microbubbles
Received: September 15, 2015
Revised: December 23, 2015
Accepted: December 23, 2015
Correspondence to:
Christian Pállson Nolsøe, MD, PhD, 
Ultrasound Section, Department 
of Gastric Surgery, Herlev Hospital, 
University of Copenhagen, Herlev 
Ringvej 75, 2730 Herlev, Denmark
Tel. +45-38683087
Fax. +45-38144189
E-mail: cnolsoe@dadlnet.dk
REVIEW ARTICLE
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in 
any medium, provided the original work is properly 
cited.
Copyright © 2016 Korean Society of 
Ultrasound in Medicine (KSUM)
How to cite this article: 
Nolsøe CP, Lorentzen T. International 
guidelines for contrast-enhanced ultrasono-
graphy: ultrasound imaging in the new 
millennium. Ultrasonography. 2016 Apr;35(2): 
89-103.
Introduction
This review deals with the four sets of international contrast-enhanced ultrasonography (CEUS) 
guidelines that have been published from 2004 to 2013 [1-5] and discusses the clinical implications 
thereof, with an emphasis on daily clinical work. The intention is to focus on common clinical scenarios 
in which CEUS plays a decisive role and to illustrate these scenarios with typical cases. According to 
the World Health Organization (WHO), two thirds of the world’s population has no access to any kind 
of medical imaging [6]. Ultrasonography, including refinements such as elastography and CEUS, has 
tremendous potential to rectify this inequity [7]. We discuss this possibility in light of four sections in 
which we comment on each set of guidelines separately with regard to their most important aspects. 
In addition, pictorial explanations drawing on clinical cases are provided to emphasize selected 
points.
2004 Guidelines for the Use of Contrast Agents in Ultrasonography
The first generation of international CEUS guidelines was issued in 2004 by the European Federation 
of Societies for Ultrasound in Medicine and Biology (EFSUMB) [1]. This article was important for 
two major reasons. First, it presented a scientific endorsement of the clinical use of contrast agents 
during ultrasonography as a decisive imaging modality in the work-up of focal liver lesions (FLLs) 
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and as an ideal tool for all phases of liver tumor ablation. Second, 
it established the acronym of CEUS to describe this technique. A 
search on Scopus performed on August 28, 2015 showed that the 
article had been cited 308 times in 135 different journals. 
These guidelines provided a detailed explanation of how to 
detect and characterize liver tumors and how to differentiate among 
various benign entities based on the enhancement pattern after 
the administration of the contrast agents, and demonstrated that 
while some refinements may be necessary, a simple algorithm can 
be used for the most common findings (Table 1). The main criterion 
for malignancy on CEUS is contrast hypo-enhancement in the late 
phase, whereas benign lesions typically remain isoenhancing to 
hyperenhancing in comparison with the surrounding normal liver 
tissue. Benign entities can reliably be differentiated from each 
other by carefully scrutinizing the arterial contrast uptake phase; for 
instance, a globular filling-in pattern is typical for hemangioma and, 
along with continued late-phase enhancement, is pathognomonic 
for this diagnosis. 
FLLs represent a very common incidental finding in modern 
medicine due to the frequent use of cross-sectional imaging in most 
high-income countries. This comes as no surprise to anyone familiar 
with abdominal ultrasonography. It may, however, be surprising to 
discover that despite the frequency of this finding, the literature 
contains no prospective data from clinically controlled studies 
describing the frequency and characterization of sonographically 
detected incidental FLLs. In a retrospective computed tomography 
(CT) study, Volk et al. [8] evaluated 1,892 examinations from a 
single institution that were performed for various reasons, but 
specifically without previously known or suspected FLL, liver 
cirrhosis, or underlying malignant disease. They identified a total of 
100 cases with unexpected FLL, and a CT diagnosis of incidentally 
discovered benign liver lesions was made in 33% of those 100 cases 
[8]. In contrast, a somewhat surprising 17% risk of malignancy was 
found by Little et al. [9] in a study of 64 patients admitted over a 
5-year period to a surgical referral department for the diagnostic 
work-up of solid liver lesions incidentally diagnosed at scanning 
of otherwise “relatively well” patients. The truth most likely lies 
somewhere between these scenarios; and in daily clinical practice 
FLLs may be encountered either incidentally or in follow-up scans 
of oncology patients. In any case, the basic questions that arise are 
identical: “Are the lesions benign or malignant?” and “If the lesion 
is malignant, then what kind of malignancy is it?”
Diagnostic ultrasonography has several important qualities 
that cannot be equally or easily achieved using CT or magnetic 
resonance imaging (MRI). Among these are features crucial to the 
two questions above, including spatial and, in particular, temporal 
resolution, as well as the practical aspects of real-time examinations 
and scanner availability. In three different European multicenter 
studies, CEUS was found to be comparable to contrast-enhanced 
CT or MRI [10-16]. The most extensive material from the German 
Ultrasound Society drew on 1,349 patients and reported a positive 
predictive value of 95.4% and a negative predictive value of 95.7% 
in differentiating between malignant and benign lesions [10]. In 
two 2011 meta-analyses of CEUS versus contrast-enhanced CT and 
MRI, the overall performance of the three modalities was statistically 
equal, with reported sensitivity and specificity ratios ranging 
from 81% to 89%. Interestingly, however, CEUS had the highest 
diagnostic odds ratio [17,18]. 
In the most recently published systematic review from the 
National Institute for Health Research of the United Kingdom [19], 
which identified a total of 854 references and included 21 studies, 
Westwood et al. [19] concluded that SonoVue (Bracco, Milan, 
Italy) CEUS can provide similar diagnostic performance to contrast-
enhanced CT and MRI for the major clinical applications: (1) the 
characterization of FLLs detected in the sonographic surveillance of 
cirrhosis patients, (2) the detection of liver metastases in patients 
with colorectal cancer, and (3) the characterization of incidentally 
detected FLLs. They made a strong statement that deserves the 
Table 1. Algorithm for using contrast-enhanced ultrasonography to characterize focal liver lesions based on the enhancement pattern 
after the administration of contrast agents 
Type Arterial phase (10-20 sec) Portal phase (30-45 sec) Late phase (>120 sec) 
Benign Hemangioma Globular enhancement Centripetal filling Iso-/hyper-enhancement 
Focal nodular hyperplasia Hyper-enhancement spoke wheel 
appearance centrifugal filling 
Moderately hyper-/
iso-enhancement 
Iso-enhancement scar (40%) 
Hepatocellular adenoma Hyper-enhancement Transition Iso-enhancement 
Malignant Hepatocellular carcinoma Hyper-enhancement Iso-/slightly hypo-enhancement Hypo-enhancement 
Metastasis, hypervascular Hyper-enhancement with/
without central necrosis 
Iso-/slightly hypo-enhancement Strong hypo-enhancement 
Metastasis, hypovascular No enhancement or peripheral rim Iso-/slightly hypo-enhancement Strong hypo-enhancement 
Time ranges in the parentheses are the delayed time for each imaging after contrast agent injection.
International CEUS guidelines
e-ultrasonography.org Ultrasonography 35(2), April 2016 91
full attention of medical professionals working in this field: “If 
the main use of liver imaging is considered to be the rapid rule-
out of malignancy, equivalent diagnostic performance may be 
sufficient for SonoVue CEUS to be preferred over other imaging 
modalities. A potential advantage of using SonoVue CEUS would be 
the option of completing the assessment at the same time as the 
initial unenhanced ultrasonography.” These conclusions are broadly 
supported [20-22] and elegantly framed by Friedrich-Rust et al. [23] 
in the following statement: “Use CEUS as first method of choice for 
the diagnostic work up of focal liver lesions if B-mode and Doppler-
ultrasonography are not conclusive.” 
In addition, CEUS has an excellent safety profile [24] and 
patient compliance, as well as no issues regarding organ function 
or radiation exposure. Therefore, when available, CEUS should be 
the first method to answer the above question of “Are the lesions 
benign or malignant?” However, CEUS cannot provide a reliable 
answer to the question “If the lesion is malignant, then what kind 
of malignancy is it?” If a histological diagnosis is deemed necessary 
for treatment planning, a tissue sample must be obtained, in which 
case an ultrasound-guided biopsy is the obvious choice [25]. Fig. 
1 (with Video clips 1-3) provides a pictorial illustration of this 
concept of the clinical work-up of newly diagnosed liver lesions 
if the scenario includes the suspicion of malignant disease. In the 
case of malignancy, a standard protocol for staging and treatment 
planning should always include full-body imaging modalities such as 
contrast-enhanced CT or MRI according to the specific malignancy 
Fig. 1. A 60-year-old woman referred for an ultrasonography to rule out gallstones incidentally diagnosed with two focal solid lesions 
in the right liver lobe located laterally in segment 6 and very closely separated. 
A. The two lesions show different appearances on B-mode imaging; one is hyperechoic (arrows) with slightly posterior enhancement and 
peripheral lie and the other is echo-poor with a halo around it (arrowheads). From the B-mode imaging alone, one would suspect the echo-
rich lesion to be a hemangioma and the echo-poor lesion to be a metastasis. A routine contrast-enhanced ultrasonography was performed 
to further characterize these lesions. B-D. The hyperechoic lesion shows globular filling-in contrast enhancement, whereas the hypoechoic 
lesion demonstrates arterial hyperenhancement (B) and contrast wash-out pattern on portal (C) and late phase (D) images, thus confirming 
the B-mode diagnosis of hemangioma and metastasis. Since the patient had no known primary cancer, the institutional tumor board 
decided that an ultrasound-guided biopsy was indicated, and a TruCut 1.2-mm core biopsy provided the diagnosis of metastatic hepatic 
adenocarcinoma of colorectal origin.
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in question.
A more common problem, however, is incidentally diagnosed, 
but sonographically benign liver lesions and the further clinical 
work-up, if any, of such lesions. In other words, the question 
is how to handle the unexpected finding of an FLL that, both 
sonographically and with respect to the patient’s symptoms and 
medical record, is deemed a benign finding. Here, as in many other 
times in life, a good piece of advice is to “keep it simple,” and the 
simplest rule one can apply is to follow the guidelines. The current 
guidelines are identical to the 2004 guidelines with regard to this 
issue, and state that CEUS is indicated for “incidental findings on 
routine ultrasonography.” This recommendation makes no further 
differentiation, and no doubt is left as to whether it is indicated in 
all cases, including the typical benign B-mode appearance. In the 
scenario of an incidentally detected lesion, this means that, unless 
the lesion is a sonographically typical cyst, a CEUS exam should be 
A B
C D
E
Fig. 2. A 53-year-old man with no history or clinical suspicion of 
cancer referred to rule out gallstones. 
A. B-mode transverse sonogram shows two hyperechoic lesions 
(between crosshairs) in both lobes of the liver. B. Another 
hyperechoic lesion (arrowheads) is defined in lower section of right 
hepatic lobe. C-E. Contrast-enhanced ultrasonography (CEUS) 
sequences illustrate arterial contrast uptake with very early (before 
normal liver tissue) enhancement of the centrally located lesion 
with a centrifugal pattern, a feeding artery consistent with the 
focal nodular hyperplasia (FNH) arterial pattern, and the slower 
centripetal globular filling-in enhancement pattern of the other two 
lesions (one in each liver lobe), consistent with the arterial pattern 
of hemangioma. 
International CEUS guidelines
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performed. This is the simplest and safest rule to follow, and it is 
also exactly what the guidelines have recommended from the first 
set of guidelines issued in 2004 to the latest guidelines issued in 
2012. If one follows this simple rule, it is not necessary to establish 
complicated algorithms to determine whether an incidental FLL 
should be further characterized on B-mode ultrasonography in order 
to reach a final decision or if a CEUS study should be next step. 
However, many experienced ultrasonography diagnosticians, 
including myself, feel that there is an issue with hemangiomas and 
that this issue deserves further commentary. Hemangioma is the 
most common tumorous condition of the liver and was found in 
an autopsy study [26] to be present in no less than 20% of men, 
although with a mean size of 5.2 mm, meaning that many of them 
were very small and most likely would have remained undiscovered 
on routine ultrasonography. In the abovementioned study of patients 
referred for further assessment [9], hemangiomas constituted 52% 
of the lesions. Hemangioma is also the most common benign tumor 
and the most common echo-rich tumor of the liver [27]. Most 
hemangiomas have very typical B-mode features, including a well-
demarcated, round, and uniformly echo-rich appearance with a 
usually peripheral lie, posterior enhancement, and a diameter less 
than 3 cm. Provided that the tumor is detected in a patient without 
any history of cancer or suspicion thereof, a diagnosis of benignity 
can be established using conventional ultrasonography with an 
estimated probability of >95%, and no further imaging is indicated 
[20,21,27]. The definitive characterization of every incidentally found 
hemangioma with CEUS would lead to a substantial workload and 
disproportionate cost. Moreover, all such efforts would be in vain 
because, according to Dietrich et al. [21], neither CEUS nor any other 
imaging modality would provide the correct diagnosis with a higher 
certainty than the ultrasonography techniques already available [9]. 
In approximately 30% of cases, however, hemangiomas demonstrate 
atypical sonographic features, and a CEUS study should be the 
next step for further characterization and to rule out malignancy. 
The same is true in the clinical scenario where a B-mode exam 
demonstrates an apparently typical hemangioma in an oncological 
patient or a patient suspected of malignancy. In such cases, CEUS 
is also the recommended next step. Fig. 2 (with Video clips 4-7) 
shows a case with a coincidental diagnosis of multiple simultaneous 
large hemangiomas in coexistence with focal nodular hyperplasia.
Guidelines and Good Clinical Practice 
Recommendations for CEUS: 2008 Update
The second generation of guidelines was published as an article 
in the February 2008 issue of European Journal of Ultrasound/
Ultraschall in der Medizin [2]. The most important element of this 
update was the inclusion of extrahepatic applications for CEUS. 
A search on Scopus on August 28, 2015 showed that the 2008 
CEUS guidelines article had been cited a total of 459 times in 139 
journals, thus exceeding the citations of the 2004 guidelines by 
50%. In addition to the initial indications, this article presented the 
best-documented newly accepted indications for the use of contrast 
agents, which were CEUS of the kidney and urinary tract, including 
the vesico-ureteric reflux, pancreas, and cerebral circulation, and 
CEUS in abdominal blunt trauma. Guidelines dealing with CEUS of 
Fig. 2. F. CEUS during the portal phase shows sustained hyperenhancement of FNH and typical slow filling-in of a large hemangioma. G. 
CEUS during the parenchymal phase still shows sustained hyperenhancement of FNH and typical slow filling-in of a large hemangioma in 
which the central areas do not display enhancement due to necrosis and scarring with both features extending long into the parenchymal 
phase. The patient subsequently underwent contrast-enhanced magnetic resonance imaging to confirm the benign nature of all lesions with 
a 1-year clinical follow-up. In the work-up of presumed benign focal liver lesions this pattern is unusual, but it is nonetheless important to 
be aware of the fact that in daily practice, multiple simultaneous hemangiomas are frequently encountered and their coexistence with FNH is 
seen more often than would be expected from pure chance [9].
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liver lesions and CEUS in ablative procedures were updated with 
the newest data available and the technical aspects were adjusted, 
but the algorithms for the interpretation of enhancement patterns 
remained fundamentally unchanged.
One application stands out in comparison with the others, and 
that is CEUS in blunt abdominal trauma. First, the trauma patient 
is one of the most commonly encountered clinical scenarios. 
Second, this new CEUS indication has a tremendous potential for 
reducing the population-level exposure to ionizing radiation. Third, 
CEUS for the evaluation of trauma patients has proven beneficial 
in clinical use on a broad scale. Prior to its inclusion in the 2008 
guidelines, only few articles with small study populations were 
available [28-30]. In recent years, several larger studies have been 
published confirming that positive outcomes were associated with 
this technique [31-40], including one prospective multicenter trial 
by Catalano et al. [41] that enrolled 156 patients with contrast-
enhanced CT used as the gold standard, and found that per-patient 
sensitivity increased from 79% for baseline ultrasonography to 
94% for CEUS. In another study of 256 patients [40] admitted to an 
emergency department with low-energy blunt abdominal trauma, 
Sessa et al. [40] found that CEUS had a much higher sensitivity 
than baseline ultrasonography in the detection of abdominal organ 
lesions (59% vs. 96%) and in the diagnosis of hemoperitoneum 
(91% vs. 95%). 
In a pediatric study of 76 children [42] admitted with isolated 
low-energy abdominal trauma, Menichini et al. [42] reported that 
the sensitivity and overall accuracy of CEUS in diagnosing solid 
organ lesions was 100%, as compared to the discouraging values 
of 39% and 44% for ultrasonography alone, with both sets of 
outcomes evaluated in comparison to contrast-enhanced CT. It was, 
however, noted that CT was more accurate than CEUS in identifying 
prognostic factors such as urinoma and active bleeding. 
These conclusions concur perfectly with the recommendations 
found in the EFSUMB CEUS guidelines on non-hepatic applications 
published in 2012 [5], which place a special emphasis on being 
aware of the availability of CEUS as an alternative to CT for 
patients with low- to moderate-energy blunt abdominal trauma 
as a supplement to the FAST protocols, especially in the pediatric 
population and as follow-up imaging modality. However, emphasis 
was also put on the fact that for high-energy trauma, CT is the 
modality of choice and that in the case of CEUS-positive findings, 
contrast-enhanced CT should most likely be performed to exclude 
active bleeding and obtain a better overall view of the entire 
abdomen [40,42]. Fig. 3 (with Video clip 8) and Fig. 4 (with Video 
clips 9, 10) illustrate the CEUS evaluation procedure in trauma cases.
The EFSUMB Guidelines and Recommendations 
on the Clinical Practice of CEUS: 2011 Update 
on Non-Hepatic Applications
This non-hepatic component of the third generation of the CEUS 
guidelines was published in the February 2012 issue of European 
Fig. 3. A 26-year-old man referred for 2 days of pain in the left flank after a physical encounter in an ice hockey match. 
The patient’s condition was stable, his blood pressure was normal, his hemoglobin levels were normal, and he was not in severe pain. The 
incident was categorized as moderate blunt trauma, and a contrast-enhanced ultrasonography (CEUS) using SonoVue was performed instead 
of contrast-enhanced computed tomography. A. B-mode ultrasonography in the left flank vaguely gives the impression of a minor intrasplenic 
hematoma (arrow) and demonstrates a tiny amount of perisplenic fluid collection. B. CEUS of the left flank clearly shows a minor hematoma 
in the lower pole of the spleen (crosshairs). The patient was treated conservatively and discharged after 2 days. Follow-up, including B-mode 
imaging and CEUS, showed healing. This figure illustrates the use of CEUS in minor to moderate blunt trauma.
A B
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represent off-label use of contrast agents and the CEUS examination 
is performed under the responsibility of the physician. The benefit of 
reducing ionizing radiation is obviously most important in children 
and fertile women, but should always be weighed against its 
possible disadvantages in the actual clinical context of the individual 
patient. This important question has been discussed in the literature 
[43,44], and while there is no easy way out of this medico-legal 
dilemma, it should always be borne in mind that the physician’s top 
priority must be the patient’s well-being. For reasons that are not 
always clear, children admitted acutely in the middle of the night 
with abdominal pain may sometimes undergo a CT scan to rule 
out serious conditions that would require surgery, which may result 
in the diagnosis of an incidental lesion that eventually requires 
further work-up in the morning. Incidentally, detected focal splenic 
lesions are one such clinical scenario that is frequently encountered 
and represents a particular dilemma. Tumors of the spleen are rare 
findings, and although most of these lesions are hemangiomas or 
hamartomas, their differentiation from malignant tumors must be 
confirmed before they can be disregarded. The spleen has a similar 
sonographic appearance to the liver and this fact sometimes brings 
about the misperception that focal spleen lesions have similar 
contrast uptake to FLLs and can therefore be interpreted according 
to the algorithm used for the liver (Table 1). Unfortunately, this is 
not the case. Although the spleen, like the liver, actually does have 
sinusoids, a very important difference from the liver is that the 
spleen has no equivalent to the portal vein and thus no dual blood 
Journal of Ultrasound/Ultraschall in der Medizin  [5]. The key 
importance of this document was the fact that it placed further 
emphasis on the inclusion of extra-hepatic applications for CEUS. 
In addition, each recommendation was graded with respect to type 
and level of evidence. A search on Scopus on August 28, 2015 
showed that the non-hepatic CEUS guidelines had been cited a total 
of 252 times in 104 different scientific journals.
The diversity of applications covered in this document is huge, 
and while many ultrasonography professionals may see a range 
of different clinical entities, no single expert is likely to master the 
evaluation of all entities. One point that deserves special mention 
with respect to the clinical use of contrast agents is the application 
of CEUS in pediatric patients, as it represents a unique medico-
legal challenge. This application is controversial and is considered 
an ethical dilemma by many clinicians. No ultrasound contrast agent 
has been approved for pediatric use, but in many clinical situations, 
CEUS could substitute for an alternative imaging modality that 
would likely include exposure to ionizing radiation or the use of 
potentially harmful iodinated contrast agents. Most drugs are not 
specifically approved for pediatric use, but when indicated, most 
physicians do not hesitate to administer the relevant drug off-label 
after informed consent from the parents. Indeed, if a necessary 
medication is not administered out of fear of using an off-label 
drug, the physician may face serious medico-legal and, it should be 
added, ethical consequences. Additionally, it should be remembered 
that most indications mentioned in the non-hepatic guidelines 
Fig. 4. A 50-year-old man with intrasplenic hematoma and a partial rupture with a large perisplenic hematoma and fluid collection 
after a car accident, visualized with contrast-enhanced computed tomography (CECT). 
Two days later, the patient was in stable condition and it was decided to substitute contrast-enhanced ultrasonography (CEUS) examination 
in place of CECT for follow-up. CEUS was performed with SonoVue and previously captured CECT scan was fused with the present CEUS 
study. A. Ultrasonography-computed tomography (CT) fused image at a follow-up 2 days after the accident shows the perisplenic fluid 
collection with a similar size as found in the CT 2 days previously. In addition, a minor laceration (arrow) is present in the spleen parenchyma 
near the medial-cranial pole, which is not as clearly visualized in the sonogram (left side) as in the corresponding fused CT image (right side). 
B. Fused CEUS and CT clearly demonstrates the small laceration (arrows), and also confirms that there is no extravasation of ultrasound 
contrast agent, thus demonstrating that bleeding from the spleen had ceased. This figure illustrates the utility of CEUS as substitute for CECT 
scans in follow-up after major trauma.
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Christian Pállson Nolsøe, et al.
96  Ultrasonography 35(2), April 2016 e-ultrasonography.org
supply. Further complicating matters, unfortunately, benign spleen 
lesions frequently show wash-out in the parenchymal phase, and the 
fact that this is a major indicator of malignancy in the work-up of 
FLLs may lead to the false-positive diagnosis of a malignant splenic 
tumor [45,46]. If presented with an otherwise healthy patient with 
a rare incidental finding that is most often benign but may lead 
to an erroneous diagnosis of malignancy on CEUS, it would seem 
prudent to perform a follow-up CEUS one and three months later. If 
malignancy still cannot be ruled out with certainty, positron emission 
tomography-CT has been suggested as a definitive step [47] before 
performing ultrasound-guided biopsy with its low but not negligible 
risk. Fig. 5 (with Video clips 11, 12) demonstrates the clinical 
problem of the false-positive CEUS diagnosis of a malignant spleen 
lesion based on parenchymal hypoenhancement. The final diagnosis, 
verified by an ultrasound-guided biopsy, was the benign finding of a 
hamartoma.
A B
Fig. 5. A 57-year-old man with abdominal pain with coincidental focal lesion of the spleen diagnosed on contrast-enhanced computed 
tomography (CECT).
The patient had no previous history of cancer. However, in a subsequent work-up, contrast-enhanced ultrasonography (CEUS) found the 
lesion suspicious and the local tumor board decided to refer the patient to our unit for a percutaneous biopsy to rule out malignancy. A. 
CECT from the referring tumor board shows a focal hypodense spleen lesion (arrow). B. B-mode ultrasonography performed in our unit 
demonstrates a slightly hypoechoic lesion (arrow) in the spleen. C. CEUS during the arterial phase demonstrates enhancement of the lesion, 
which is slightly delayed and hypoenhancing (arrows) compared to the surrounding normal spleen tissue. D. CEUS demonstrates strong 
hypoenhancement (arrows), also known as wash-out, in the late parenchymal phase. From CEUS-guided biopsy, the final diagnosis was 
splenoma, which is a benign hamartoma-like tumor of the spleen. In conclusion, CEUS wash-out is not indicative of a strong suspicion of 
malignancy, and a clinical examination and positron emission tomography-computed tomography should be considered before biopsy in 
patients with no other indications of malignant disease. This figure illustrates that wash-out in spleen lesion CEUS is not equivalent to the 
CEUS of focal liver lesions and cannot be taken as a strong indicator of malignancy.
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Guidelines and Good Clinical Practice 
Recommendations for CEUS in the Liver: 
Update 2012: A WFUMB-EFSUMB Initiative in 
Cooperation with Representatives of AFSUMB, 
AIUM, ASUM, FLAUS and ICUS
This third generation of CEUS liver guidelines was published 
simultaneously in the February 2013 issues of Ultrasound in Medicine 
and Biology and European Journal of Ultrasound/Ultraschall in 
der Medizin [3,4]. The key importance of this document is the 
fact it presented a worldwide consensus from a wide and truly 
representative range of medical professional bodies on the usage of 
CEUS and the interpretation of enhancement patterns with clinically 
approved contrast agents for liver applications. The article describes 
the use of available different contrast agents licensed across the 
world for use in the work-up of clinical scenarios related to the liver. 
These contrast agents are all fluorocarbons, sometimes referred 
to as perfluorocarbons, and also sometimes called organofluorine 
compounds. They are biologically inert gases at atmospheric pressure 
that are encapsulated in a lipid membranous shell. Thus, they do not 
interact with metabolism, can be administered regardless of renal 
and liver functionality, and have an extremely high safety profile, as 
specifically documented for SonoVue [24] (marketed as Lumason 
in the United States but not licensed for the liver), which is a sulfur 
hexafluoride introduced in 2001 by Bracco SpA (Milan, Italy) and 
licensed in Europe, China, India, Korea, Hong Kong, New Zealand, 
Singapore, and Brazil. The other two contrast agents are chemically 
very closely related and marketed under the names Definity/Luminity, 
A B
Fig. 6. A 77-year-old woman under surveillance for cirrhosis.
A. B-mode and color Doppler ultrasonography demonstrate an interim nodule (crosshairs) in the right hepatic lobe. B. Sonazoid contrast-
enhanced ultrasonography (CEUS) shows arterial hyper-enhancement (arrows) with earlier onset than the surrounding liver tissue. 
C. Sonazoid CEUS-guided 1.2-mm TruCut biopsy of an isoenhancing lesion in the postvascular phase was performed at 13 minutes 
post-contrast. The biopsy revealed well-differentiated hepatocellular carcinoma. D. An image from a Sonazoid CEUS shows sustained 
isoenhancement in the postvascular phase at 31 minutes post-contrast. This figure illustrates the fact that with Sonazoid CEUS of well-
differentiated hepatocellular carcinomas, in approximately 50% of cases, no enhancement defect is noted at 30 minutes post-contrast, 
potentially warranting a biopsy.
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which is an octafluoropropane compound introduced in 2001 by 
Lantheus Medical (Billerica, MA, USA) and licensed in Canada and 
Australia, and Sonazoid, a perfluorobutane introduced in 2007 by 
Daiichi-Sankyo (GE, Tokyo, Japan) and licensed in Japan and South 
Korea, and recently also in Denmark and Norway. 
A search on Scopus on August 28, 2015 showed that the 2012 
update of the liver CEUS guidelines had been cited a total of 170 
times in 97 scientific journals, with 80 citations in 52 journals of the 
version of the article printed in Ultrasound in Medicine and Biology 
and 90 citations in 45 journals of the version printed in European 
Journal of Ultrasound/Ultraschall in der Medizin. Compared to the 
two previous generations of CEUS guidelines, this most recent 
update provided recommendations on two new topics: information 
related to Sonazoid and a recommendation to use CEUS for biopsy 
guidance to increase the retrieval rate of percutaneous ultrasound-
guided biopsy and to reduce the frequency of negative microscopy 
results [48-52].
Sonazoid, remarkably and completely unlike the other two 
contrast agents, has a so-called postvascular phase in which the 
contrast agent leaves the vascular bed and enters the parenchymal 
interstitium. This postvascular phase starts 10 minutes after injection 
and may last more than 30 minutes, and is caused by the Kupffer 
cell uptake of this particular contrast agent, which is very similar 
to that of the liver-specific MRI contrast agents often referred 
to as superparamagnetic iron oxide (SPIO) [53]. This mechanism 
ensures the uniform enhancement of normal liver tissue. Sonazoid, 
according to Kudo et al. [54-56] has been used with particular 
frequency in the work-up of hepatocellular carcinoma (HCC) in the 
cirrhotic liver because the typical HCC contains no Kupffer cells 
and thus stands out as an enhancement defect in the postvascular 
phase [57]. Unfortunately, however, between 50% and 70% of well 
differentiated HCCs-corresponding to approximately 10%-15% of 
HCCs in the cirrhotic population-may not demonstrate this typical 
enhancement defect [58,59], and in this situation a biopsy may be 
indicated to achieve the correct diagnosis [56,60,61]. Fig. 6 (with 
Video clips 13-15) demonstrates a clinical scenario such as this, 
in which a CEUS-guided biopsy was performed utilizing Sonazoid. 
The benefit of CEUS-guided biopsy was reported by Bang et al. [50] 
as early as 2000 and later was proven by Wu et al. [49] to increase 
the diagnostic accuracy rate by up to 10% by directing the biopsy 
towards contrast-enhanced areas. Schlottman et al. [48] suggested 
a different approach, in which CEUS was used to identify previously 
non-visualized lesions that were more easily accessible for biopsy, 
and this technique later received support from Yoon et al. [51,52]. 
In addition to the work-up of liver lesions, which has been 
described in detail above, the single other major indication for CEUS 
that has existed since the initial development of this technique is 
assistance in percutaneous ablative procedures. In many institutions 
around the world, ultrasonography is the preferred guidance 
modality for ablation. However, with regard to treatment evaluation, 
it is not sufficient to examine morphology alone, since tissue 
viability cannot be judged without knowledge of perfusion, which 
necessitates the use of contrast agents. Additionally, the ablation 
volume itself occasionally may present on B-mode ultrasonography 
very similarly to the surrounding normal tissue, again making the use 
of contrast agents necessary. Thus, before the availability of CEUS, 
Fig. 7. Contrast-enhanced ultrasonography (CEUS) assistance during the course of follow-up after percutaneous ablation.
A. On B-mode ultrasonography, the ablation volume (crosshairs) cannot be evaluated for viability on 6-week follow-up after the microwave 
ablation of a solitary colorectal liver metastasis. B. SonoVue CEUS shows a well-demarcated ablation cavity without any enhancement, 
indicating successful ablation with no suspicion of skipped areas and no viable tissue. 
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it was mandatory to include CT or MRI in the follow-up protocol of 
ablation therapy. With the advent of CEUS, ultrasonography can play 
a pivotal role in all aspects of percutaneous ablation from diagnosis, 
through guidance and procedural monitoring [62-64], to follow-up 
examinations after percutaneous ablation. Recent reports, including 
one multicenter study, have concluded that CEUS is comparable in 
performance to both contrast-enhanced CT and MRI [65,66] in the 
evaluation of ablation treatment for local recurrence, the assessment 
of ablation volume viability, and the identification of new 
metastases. Fig. 7 (with Video clip 16) and Fig. 8 (with Video clip 
17) illustrate how CEUS is an indispensable tool in ultrasonography 
follow-up after percutaneous ablation, both with respect to imaging 
and as guidance for percutaneous biopsy in the case of relapse.
Conclusion
The introduction of contrast agents for ultrasonography has had an 
overwhelming impact on modern medicine. CEUS has dramatically 
expanded the field of medical ultrasound and opened up a 
completely new world in patient management. In liver imaging, 
CEUS has come to play a decisive role, due to its excellent temporal 
resolution, and the use of CEUS has changed the classic indications 
for biopsies and limited biopsy to equivocal cases. CEUS in many 
aspects is comparable to contrast-enhanced CT and MRI [1-
4,10,15-19,22,23,65], and CEUS has changed the algorithms for 
medical imaging in high-income industrialized societies. According 
to the WHO, two thirds of the world’s population has no access 
to medical imaging [6]. Ultrasonography including CEUS has the 
potential to rectify this inequality, and if CEUS were incorporated 
as an integral part of ultrasonography, it would be realistic to 
bring state-of-the-art medical imaging to the entire world. Just 
imagine how the lack of availability of contrast agents would limit 
the value and reduce the impact of CT or MRI! This is the scenario 
ultrasonography must face in many countries where contrast agents 
have not been approved. The World Federation for Ultrasound in 
Medicine and Biology has as its overall purpose to bring the use 
of medical ultrasound to every corner of the world. Used together 
with all its technical refinements, including CEUS, ultrasonography 
is a second-to-none multipotent imaging tool capable of providing 
state-of-the-art imaging to the entire world in the new millennium.
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Fig. 8. Contrast-enhanced ultrasonography (CEUS) assistance during the course of follow-up after percutaneous ablation with CEUS-
guided biopsy for suspicious local recurrence.
A. One-year follow-up B-mode ultrasonography after the radiofrequency ablation of hepatocellular carcinoma (HCC) indicates the suspicion 
of a local recurrence (arrows). B. SonoVue CEUS well delineates the suspicious recurrent lesions (arrows) more clearly. After reinjection of 
SonoVue, a CEUS-guided cytology biopsy was directed towards the suspected recurrence area, and microscopy confirmed the diagnosis of 
local recurrence of HCC.
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Video clip 1. In the arterial phase, the hyperechoic lesion shows 
globular filling-in contrast enhancement, whereas the hypoechoic 
lesion demonstrated arterial hyperenhancement (http://dx.doi.
org/10.14366/usg.15057.v001).
Video clip 2. During the portal phase, the hyperechoic lesion 
continues the same pattern of contrast filling-in enhancement, 
whereas the hypoechoic lesion shows a contrast wash-out pattern, 
thus confirming the B-mode diagnosis of hemangioma and 
metastasis (http://dx.doi.org/10.14366/usg.15057.v002).
Video clip 3. During the late phase, the same contrast enhancement 
pattern as in Video clip 2C continues (http://dx.doi.org/10.14366/
usg.15057.v003).
Video clip 4. Contrast-enhanced ultrasonography sequence 
illustrates arterial contrast uptake with very early (before normal liver 
tissue) enhancement of the central lesion with a centrifugal pattern, 
a feeding artery consistent with the focal nodular hyperplasia arterial 
pattern, and the slower centripetal globular filling-in enhancement 
pattern of the larger lesion consistent with the arterial pattern of 
hemangioma (http://dx.doi.org/10.14366/usg.15057.v004).
Video clip 5. Contrast-enhanced ultrasonography sequence 
captured immediately after Video clip 4, illustrates arterial contrast 
uptake with slow centripetal globular filling-in enhancement 
pattern of another more peripherally located lesion consistent with 
the arterial pattern of hemangioma (http://dx.doi.org/10.14366/
usg.15057.v005).
Video clip 6. Contrast-enhanced ultrasonography from the portal 
phase shows the typical slow filling-in of a large hemangioma in 
which the central areas do not display enhancement, likely due to 
necrosis and scarring, as well as the sustained hyperenhancement of 
focal nodular hyperplasia (http://dx.doi.org/10.14366/usg.15057.
v006).
Video clip 7. A contrast-enhanced ultrasonography sequence 
in the parenchymal phase shows the typical slow filling-in of 
a large hemangioma in which the central areas do not display 
enhancement, as well as the sustained hyperenhancement of focal 
nodular hyperplasia, with both features extending long into the 
parenchymal phase (http://dx.doi.org/10.14366/usg.15057.v007).
Video clip 8. In a patient of minor spleen trauma, contrast-
enhanced ultrasonography of the left flank clearly shows a 
small hematoma in the lower pole of the spleen (http://dx.doi.
org/10.14366/usg.15057.v008). 
Video clip 9. Ultrasonography-computed tomography (CT) fusion 
at follow-up two days after the accident shows the perisplenic 
fluid collection with a similar size as found in the CT imaging two 
days previously. In addition, a minor laceration is present in the 
spleen parenchyma near the medial-cranial pole, which is not as 
clearly visualized in the sonogram as in the corresponding fused 
CT (http://dx.doi.org/10.14366/usg.15057.v009).
Video clip 10. A fused contrast-enhanced ultrasonography and 
computed tomography image clearly demonstrates the small 
laceration, and also confirms that no extravasation of the ultrasound 
contrast agent was present, thus demonstrating that bleeding from 
the spleen had ceased (http://dx.doi.org/10.14366/usg.15057.
v010).
Video clip 11. A contrast-enhanced sonogram in the arterial 
phase performed in our unit demonstrates arterial enhancement, 
which is slightly delayed and slightly hypoenhancing compared to 
the surrounding normal spleen tissue (http://dx.doi.org/10.14366/
usg.15057.v011).
Video clip 12. By a contrast-enhanced ultrasonography-guided 
biopsy, the final diagnosis was splenoma, a benign hamartoma-like 
tumor of the spleen (http://dx.doi.org/10.14366/usg.15057.v012).
Video clip 13. A Sonazoid contrast-enhanced ultrasonography 
shows arterial hyperenhancement with earlier onset than the 
surrounding liver tissue (please note that there is in addition a 
simple cyst in the patients right upper corner of the Video clip 
which appears typically totally non-enhancing and echopoor) 
(http://dx.doi.org/10.14366/usg.15057.v013).
Video clip 14. A Sonazoid contrast-enhanced ultrasonongraphy-
guided 1.2-mm TruCut biopsy of an isoenhancing lesion in the 
postvascular phase at 13 minutes post-contrast revealed well-
differentiated hepatocellular carcinoma (http://dx.doi.org/10.14366/
usg.15057.v014).
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Video clip 15. A Sonazoid contrast-enhancing ultrasonography 
shows sustained isoenhancement in the postvascular phase at 31 
minutes post-contrast (http://dx.doi.org/10.14366/usg.15057.
v015).
Video clip 16. SonoVue contrast-enhanced ultrasonography shows 
a well-demarcated ablation cavity without any enhancement, 
indicating successful ablation with no suspicion of skipped areas 
and no viable tissue (http://dx.doi.org/10.14366/usg.15057.v016).
Video clip 17. After the reinjection of SonoVue, a contrast-
enhanced ultrasonography-guided cytology biopsy was directed 
towards the suspected recurrence area, and microscopy confirmed 
the diagnosis of local recurrence (http://dx.doi.org/10.14366/
usg.15057.v017).
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